CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Clinical Investigation

• Publication date

  2007-12-03

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.1172/JCI32481PMID 18060030PMCID PMC2096455
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Restoration of p53 function leads to tumour regression in vivo

  2007cited by this paper
• Cell type and DNA damage specific response of human skin cells to environmental agents.

  2007cited by this paper
• A role for neutrophil elastase in solar elastosis.

  2007cited by this paper
• Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide.

  2007cited by this paper
• Reactivation of the p53 Tumor Suppressor Pathway by a Stapled p53 Peptide

  2007cited by this paper
• Recruiting the Cell's Own Guardian for Cancer Therapy

  2007cited by this paper
• Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

  2007cited by this paper
• Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells.

  2006cited by this paper
• Spectral and dose dependence of ultraviolet radiation-induced immunosuppression.

  2006cited by this paper
• Dissecting p53-dependent apoptosis

  2006cited by this paper
• JC‐1, a sensitive probe for a simultaneous detection of P‐glycoprotein activity and apoptosis in leukemic cells

  2006cited by this paper
• Contributions of human tumor xenografts to anticancer drug development.

  2006cited by this paper
• Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts.

  2006cited by this paper
• Cyclosporin A does not protect the disruption of the inner mitochondrial membrane potential induced by potassium ionophores in intact K562 cells

  2006cited by this paper
• Mutant p53 melanoma cell lines respond differently to CP‐31398‐induced apoptosis

  2005cited by this paper
• Acridine derivatives activate p53 and induce tumor cell death through bax

  2005cited by this paper
• Dose-dependent effects of UVB-induced skin carcinogenesis in hairless p53 knockout mice.

  2005cited by this paper
• p53 translocation to mitochondria precedes its nuclear translocation and targets mitochondrial oxidative defense protein-manganese superoxide dismutase.

  2005cited by this paper
• Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti–IGF-IR antibody

  2005cited by this paper
• Mitochondrial permeability transition as a source of superoxide anion induced by the nitroaromatic drug nimesulide in vitro.

  2005cited by this paper
• Cancer genes and the pathways they control

  2004cited by this paper
• [Tumor suppressor gene p53 and molecular targeting therapy].

  2004cited by this paper
• Targeting p53 by PTD-mediated transduction.

  2004cited by this paper
• Effects of PRIMA‐1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion

  2004cited by this paper
• Reactive oxygen species-producing site in radiation and hydrogen peroxide-induced apoptosis of human peripheral T cells: Involvement of lysosomal membrane destabilization.

  2004cited by this paper
• In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

  2004cited by this paper
• In Vivo Mitochondrial p53 Translocation Triggers a Rapid First Wave of Cell Death in Response to DNA Damage That Can Precede p53 Target Gene Activation

  2004cited by this paper
• Reactive oxygen species-producing site in radiation-induced apoptosis of human peripheral T cells: involvement of lysosomal membrane destabilization.

  2004cited by this paper
• Tumor suppressor gene therapy.

  2003cited by this paper
• Small molecules that reactivate mutant p53.

  2003cited by this paper
• Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation.

  2003cited by this paper
• CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death

  2003cited by this paper
• Restoring p53-Dependent Tumor Suppression

  2003cited by this paper
• Stabilization of p53 by CP-31398 Inhibits Ubiquitination without Altering Phosphorylation at Serine 15 or 20 or MDM2 Binding

  2003cited by this paper
• UVB-induced mutations in human key gatekeeper genes governing signalling pathways and consequences for skin tumourigenesis

  2003cited by this paper
• Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription.

  2003cited by this paper
• TP53 mutations in human skin cancers

  2003cited by this paper
• p53 has a direct apoptogenic role at the mitochondria.

  2003cited by this paper
• The Mutant p53-Conformation Modifying Drug, CP-31398, Can Induce Apoptosis

  2002cited by this paper
• The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic Bax/mitochondrial/caspase-9 pathway.

  2002cited by this paper
• Characterization of the p53-rescue drug CP-31398 in vitro and in living cells

  2002cited by this paper
• P53: An ubiquitous target of anticancer drugs

  2002cited by this paper
• UV damage, DNA repair and skin carcinogenesis.

  2002cited by this paper
• Stage-specific Alterations of Cyclin Expression During UVB-induced Murine Skin Tumor Development¶

  2002cited by this paper
• Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

  2002cited by this paper
• UV-induced DNA damage and mutations in Hupki (human p53 knock-in) mice recapitulate p53 hotspot alterations in sun-exposed human skin.

  2001cited by this paper
• Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling

  2001cited by this paper
• Cell cycle control as a basis for cancer drug development (Review).

  2000cited by this paper
• Surfing the p53 network

  2000cited by this paper
• Novel Approaches to Chemoprevention of Skin Cancer

  2000cited by this paper
• Mutations in cancer genes of UV-induced skin tumors of hairless mice.

  1999cited by this paper
• Pharmacological rescue of mutant p53 conformation and function.

  1999cited by this paper
• Mutations in cancer genes of UV-induced skin tumors of hairless mice.

  1999cited by this paper
• Conformational and Molecular Basis for Induction of Apoptosis by a p53 C-terminal Peptide in Human Cancer Cells*

  1999cited by this paper
• Regulation of p53 downstream genes.

  1998cited by this paper
• Small peptides activate the latent sequence-specific DNA binding function of p53.

  1995cited by this paper
• Mitochondrial membrane potential in single living adult rat cardiac myocytes exposed to anoxia or metabolic inhibition.

  1995cited by this paper
• Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines.

  1994cited by this paper
• Analysis of the p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers.

  1994cited by this paper
• Status of the p53 tumor suppressor gene in human squamous carcinoma cell lines.

  1992cited by this paper
• Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1.

  1991cited by this paper
• The p53 tumour suppressor gene

  1991cited by this paper
• J-aggregate formation of a carbocyanine as a quantitative fluorescent indicator of membrane potential.

  1991cited by this paper
• THE BIOLOGY OF THE (6–4) PHOTOPRODUCT

  1989cited by this paper

• CP-31398 restored the functional condensates of R175H p53 by stabilizing the zinc-binding domain and 251-258 segment.

  2026cites this paper
• The regulation of CP-31398 on liquid-liquid phase separation of p53.

  2026cites this paper
• TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a 3 comprehensive overview of targeted approaches

  2026cites this paper
• 18β-Glycyrrhetinic acid reduces skin damage from UVB exposure by inhibiting the MyD88/MAPK signaling pathway.

  2026cites this paper
• p53 Aggregation in cancer: Molecular mechanisms, functional disruptions, and targeted therapies.

  2025cites this paper
• p53 in colorectal cancer: from a master player to a privileged therapy target

  2025cites this paper
• In Silico Development of PABA-substituted Pyrimidine Derivatives Targeting Mutant p53 for Precision Therapy in Oral Squamous Cell Carcinoma

  2025cites this paper
• P53 and the Ultraviolet Radiation-Induced Skin Response: Finding the Light in the Darkness of Triggered Carcinogenesis

  2024cites this paper
• TP53 gene status can promote sensitivity and resistance to chemotherapeutic drugs and small molecule signal transduction inhibitors.

  2024cites this paper
• From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy

  2024cites this paper
• Comparative Molecular Docking of Apigenin and Luteolin Versus Conventional Ligands for TP-53, pRb, APOBEC3H, and HPV-16 E6: Potential Clinical Applications in Preventing Gynecological Malignancies

  2024influential citation
• Integrated stress response (ISR) activation and apoptosis through HRI kinase by PG3 and other p53 pathway-restoring cancer therapeutics

  2024cites this paper
• Twenty years of Gendicine® rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncology

  2023cites this paper
• Targeting Biomolecular Condensation and Protein Aggregation against Cancer.

  2023cites this paper
• Nano-liposomal zein hydrolysate for improved apoptotic activity and therapeutic index in lung cancer treatment

  2022cites this paper
• Therapeutic restoring p53 function with small molecule for oncogene-driven non-small cell lung cancer by targeting serine 392 phosphorylation.

  2022cites this paper
• Restoring p53 Function in Head and Neck Squamous Cell Carcinoma to Improve Treatments

  2022cites this paper
• p53 amyloid aggregation in cancer: function, mechanism, and therapy

  2022cites this paper
• Mutant p53 reactivator SLMP53-2 hinders ultraviolet B radiation-induced skin carcinogenesis.

  2021cites this paper
• TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?

  2021cites this paper
• Aberrant phase separation and cancer

  2021cites this paper
• The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy

  2021cites this paper
• A Review of Principal Studies on the Development and Treatment of Epithelial Ovarian Cancer in the Laying Hen Gallus gallus.

  2021cites this paper
• Crosslink between p53 and metastasis: focus on epithelial–mesenchymal transition, cancer stem cell, angiogenesis, autophagy, and anoikis

  2021cites this paper
• The Role of p53 in Progression of Cutaneous Squamous Cell Carcinoma

  2021cites this paper
• Combination of a p53-activating CP-31398 and an MDM2 or a FAK inhibitor produces growth suppressive effects in mesothelioma with wild-type p53 genotype

  2020cites this paper
• 2-[(4-Hydroxybenzyl) Amino] Phenol (HBAP) Restores the Mutated p53 to the Level Similar to That of Wild-Type p53 Protein and Inhibits Breast Cancer Growth in vivo to by Inducing Tumor Cells Apoptosis

  2020cites this paper
• P53 in skin cancer: From a master player to a privileged target for prevention and therapy.

  2020cites this paper
• Genetic and environmental factors underlying keratinocyte carcinoma risk.

  2020cites this paper
• Recent Synthetic Approaches towards Small Molecule Reactivators of p53

  2020cites this paper
• Expression of Wild-Type p53 by Curcumin, Alpinetin and Flavokawain B in Colorectal Cancer cells Expressing R273H Mutant p53

  2020cites this paper
• BRCA1/P53: Two strengths in cancer chemoprevention.

  2020cites this paper
• Molecular chaperone HspB2 inhibited pancreatic cancer cell proliferation via activating p53 downstream gene RPRM, BAI1, and TSAP6

  2020cites this paper
• In vitro evaluation of anti-epidermoid cancer activity of Acanthus ebracteatus protein hydrolysate and their effects on apoptosis and cellular proteins

  2019cites this paper
• Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors

  2019cites this paper
• Targeted therapies for non-HPV-related head and neck cancer: challenges and opportunities in the context of predictive, preventive, and personalized medicine

  2019cites this paper
• The clinical course of actinic keratosis correlates with underlying molecular mechanisms

  2019cites this paper
• Improving cancer therapy with new p53-activating agents

  2019cites this paper
• Awakening the “guardian of genome”: reactivation of mutant p53

  2018cites this paper
• Development of transethosomes formulation for dermal fisetin delivery: Box–Behnken design, optimization, in vitro skin penetration, vesicles–skin interaction and dermatokinetic studies

  2018cites this paper
• Selective killing of human breast cancer cells by the styryl lactone (R)-goniothalamin is mediated by glutathione conjugation, induction of oxidative stress and marked reactivation of the R175H mutant p53 protein

  2018cites this paper
• Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer.

  2018cites this paper
• Gemcitabine treatment induces endoplasmic reticular (ER) stress and subsequently upregulates urokinase plasminogen activator (uPA) to block mitochondrial-dependent apoptosis in Panc-1 cancer stem-like cells (CSCs)

  2017cites this paper
• Molecularly targeted therapies for p53-mutant cancers

  2017cites this paper
• Crude Extracts, Flavokawain B and Alpinetin Compounds from the Rhizome of Alpinia mutica Induce Cell Death via UCK2 Enzyme Inhibition and in Turn Reduce 18S rRNA Biosynthesis in HT-29 Cells

  2017cites this paper
• Naproxen Inhibits UVB‐induced Basal Cell and Squamous Cell Carcinoma Development in Ptch1+/−/SKH‐1 Hairless Mice

  2017cites this paper
• Correction: Crude Extracts, Flavokawain B and Alpinetin Compounds from the Rhizome of Alpinia mutica Induce Cell Death via UCK2 Enzyme Inhibition and in Turn Reduce 18S rRNA Biosynthesis in HT-29 Cells

  2017cites this paper
• When the guardian sleeps: Reactivation of the p53 pathway in cancer.

  2017cites this paper
• Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease?

  2016cites this paper
• Piperlongumine exerts cytotoxic effects against cancer cells with mutant p53 proteins at least in part by restoring the biological functions of the tumor suppressor.

  2016cites this paper
• Genomics of SCC: Tumor Formation, Progression, and Future Therapeutic Implications for High-Risk Cutaneous Squamous Cell Carcinoma

  2016cites this paper
• Design and synthesis of a C7-aryl piperlongumine derivative with potent antimicrotubule and mutant p53-reactivating properties.

  2016cites this paper
• Targeting cancer stem cells with p53 modulators

  2016cites this paper
• CP-31398 inhibits the growth of p53-mutated liver cancer cells in vitro and in vivo

  2015cites this paper
• Targeting Oncogenic Mutant p53 for Cancer Therapy

  2015cites this paper
• Targeting mTOR and p53 Signaling Inhibits Muscle Invasive Bladder Cancer In Vivo

  2015cites this paper
• TP53 modulating agent, CP-31398 enhances antitumor effects of ODC inhibitor in mouse model of urinary bladder transitional cell carcinoma.

  2015cites this paper
• CP-31398 prevents the growth of p53-mutated colorectal cancer cells in vitro and in vivo

  2015cites this paper
• Tumor suppressor p53 and its gain-of-function mutants in cancer.

  2014cites this paper
• Functional repair of p53 mutation in colorectal cancer cells using trans-splicing

  2014cites this paper
• Role of p53 in Apoptosis and Cancer Therapy

  2014cites this paper
• p53 in Head and Neck Cancer

  2014cites this paper
• DNA repair systems

  2014cites this paper
• Hair follicle disruption facilitates pathogenesis to UVB-induced cutaneous inflammation and basal cell carcinoma development in Ptch(+/-) mice.

  2014cites this paper
• Nitric oxide-releasing sulindac is a novel skin cancer chemopreventive agent for UVB-induced photocarcinogenesis.

  2013cites this paper
• Molecular basis for the tissue specificity of β-catenin oncogenesis

  2013cites this paper
• Quercetin Induces Mitochondrial Mediated Apoptosis and Protective Autophagy in Human Glioblastoma U373MG Cells

  2013cites this paper
• p53-stabilizing agent CP-31398 prevents growth and invasion of urothelial cancer of the bladder in transgenic UPII-SV40T mice.

  2013cites this paper
• A compound CP-31398 suppresses excitotoxicity-induced neurodegeneration.

  2013cites this paper
• Targeting Mutant p53 for Improved Cancer Therapy

  2013cites this paper
• p53 in the Clinics

  2013cites this paper
• Novel recurrent neural network for modelling biological networks: Oscillatory p53 interaction dynamics

  2013cites this paper
• Chemopreventive effects of the p53-modulating agents CP-31398 and Prima-1 in tobacco carcinogen-induced lung tumorigenesis in A/J mice.

  2013cites this paper
• Milestones in photocarcinogenesis.

  2013cites this paper
• Fisetin inhibits growth, induces G2/M arrest and apoptosis of human epidermoid carcinoma A431 cells: role of mitochondrial membrane potential disruption and consequent caspases activation

  2013cites this paper
• Targeting the p53 pathway.

  2013cites this paper
• Pharmacokinetics and tissue and tumor exposure of CP-31398, a p53-stabilizing agent, in rats

  2012cites this paper
• Combined inhibition of p38 and Akt signaling pathways abrogates cyclosporine A-mediated pathogenesis of aggressive skin SCCs.

  2012cites this paper
• From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma.

  2012cites this paper
• Genotoxicity of the cancer chemopreventive drug candidates CP-31398, SHetA2, and phospho-ibuprofen.

  2012cites this paper
• Translational approaches targeting the p53 pathway for anti‐cancer therapy

  2012cites this paper
• Therapeutic reactivation of mutant p53 protein by quinazoline derivatives

  2012cites this paper
• The mitochondrial pathways of apoptosis.

  2012influential citation
• p53—Guardian Angel and Archangel

  2012cites this paper
• Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells

  2012cites this paper
• Beyond effector caspase inhibition

  2011cites this paper
• Microtubule-targeted agents: when mitochondria become essential to chemotherapy.

  2011cites this paper
• Non-genotoxic p53-activators and their significance as antitumor therapy of future.

  2011cites this paper
• Resuscitating wild-type p53 expression by disrupting ceramide glycosylation: a novel approach to target mutant p53 tumors.

  2011cites this paper
• Liver kinase B1 (LKB1) in the pathogenesis of UVB-induced murine basal cell carcinoma.

  2011cites this paper
• Analyse du rôle de la voie p53 dans la réponse des sarcomes des tissus mous au traitement par TNF-alpha

  2011cites this paper
• Procarcinogenic effects of cyclosporine A are mediated through the activation of TAK1/TAB1 signaling pathway.

  2011cites this paper
• Mutant p53 exhibits trivial effects on mitochondrial functions which can be reactivated by ellipticine in lymphoma cells

  2011cites this paper
• Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells.

  2011cites this paper
• Pharmacological activation of p53 in cancer cells.

  2011cites this paper
• Cyclosporine a mediates pathogenesis of aggressive cutaneous squamous cell carcinoma by augmenting epithelial‐mesenchymal transition: Role of TGFβ signaling pathway

  2011influential citation
• Determination and stability of CP-31398 in plasma from experimental animals by LC-MS/MS.

  2011cites this paper
• Subchronic oral toxicity and metabolite profiling of the p53 stabilizing agent, CP-31398, in rats and dogs.

  2011cites this paper
• Pathogenesis of nonmelanoma skin cancers in organ transplant recipients.

  2011cites this paper
• The antiproliferative function of violacein‐like purple violet pigment (PVP) from an Antarctic Janthinobacterium sp. Ant5‐2 in UV‐induced 2237 fibrosarcoma

  2011cites this paper